Navigation Links
Exagen's Corporate Expansion Creates Job Opportunities in New Mexico
Date:1/25/2011

ALBUQUERQUE, N.M., Jan. 25, 2011 /PRNewswire/ -- Exagen Diagnostics, Inc., a specialty diagnostics laboratory that discovers, develops and markets proprietary tests, announced today the completion of the company's office expansion at the University of New Mexico Science and Technology Park. The expansion, which includes new space for both offices and a laboratory, allows Exagen to accommodate growing test volume for its gastroenterology products and the transition of the company's newly acquired rheumatology diagnostic products to Albuquerque.

"We are pleased to see the rapid adoption of our gene expression tests for the diagnosis of Inflammatory Bowel Disease and Irritable Bowel Syndrome," said Scott Glenn, Exagen CEO. "New Mexico is a wonderful environment to build a business, and our success will create an ongoing need for employees in operations, research and development, sales and marketing."

In the coming year, Exagen plans to double its sales force and hire 16 additional employees, including technical lab personnel, marketing directors, customer service and billing staff. Sales force personnel will be geographically based; all others will be based in Albuquerque.

In addition to commercial laboratory testing, Exagen has an active Research and Development group that will use some of the new space to complete various programs in both rheumatology and gastroenterology. With a commitment to personalized medicine, Exagen is focused on discovering and developing tests for individualized diagnostic information. A number of products are expected to be launched in 2011 and 2012.

About Exagen Diagnostics, Inc.

Exagen Diagnostics is the emerging leader in laboratory-discovered and developed diagnostic tests specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. Using Coperna®, the company's proprietary, algorithm-driven computational tool and search engine that runs on high-performance computational clusters, it combines the ability to process massive amounts of data contained in genomic datasets with intelligent, rapid search methods. Coperna's targeted and precise discovery model has no conventional equivalent in the industry as it can identify relevant marker sets with superior sensitivity and specificity relative to markers identified via traditional analytical methods. For more information, please visit www.exagen.com.


'/>"/>
SOURCE Exagen Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
2. Genta Incorporated Announces Third Quarter 2007 Financial Results
3. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
4. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
5. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
6. AMT Intends to Incorporate Additional Data to its Marketing Authorization Dossier for Glybera(R)
7. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
8. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
9. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
10. Impact Medical Solutions Announces Appointment of New Director and Corporate Update
11. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... 2017 RK Logistics Group, Inc. was awarded ... its Fremont, CA headquarters facility where ... and San Jose for hi-tech, pharmaceutical ... , with its Fremont Innovation District, is excited to ... powerful resource to the hundreds of biotech, pharma and biomed ...
(Date:7/12/2017)... 12, 2017  Eli Lilly and Company (NYSE: ... companies to resolve pending patent litigation in the U.S. District ... regarding the Cialis ® (tadalafil) unit dose patent. ... 2020. As part of the agreement, Cialis exclusivity is now ... "The unit dose patent for Cialis is valid ...
(Date:7/11/2017)... Md. , July 11, 2017  The global ... estimated revenues of approximately $394.1 million in 2016.  Although ... trend of solid growth, in particular as a result ... clinical practice, and the recent introduction of a significant ... need for less-invasive testing of tumor biomarkers to guide ...
Breaking Medicine Technology:
(Date:7/27/2017)... ... July 27, 2017 , ... Healthy eating isn’t always easy. Currently, more than 80 percent ... time, many Americans overeat refined grains and sugar. This trend may help explain why the ... the U.S. are obese. , As a culture, we seem to have food on the ...
(Date:7/27/2017)... ... July 27, 2017 , ... Cremations recently surpassed traditional ... Directors Association, this trend is expected to continue with over 70% of Americans projected ... growing demand for new innovations that enable families to celebrate the life of a ...
(Date:7/26/2017)... ... July 26, 2017 , ... Written By: Ashley D. Beall, ... in drug therapy for patients living with relapsing and primary multiple sclerosis that ... cell targeted therapy that has been proven to significantly reduce signs of disease ...
(Date:7/26/2017)... ... ... It may be hard to imagine that the basic necessities that developed countries ... that many developed countries consider rare or eradicated, like measles, are still a rite ... an upcoming segment of "Success Files", actor Rob Lowe will introduce a new segment ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... the cloud ; today announced the availability of its latest data protection solution ... use control console for Data Discovery, Classification, Encryption and Digital Rights Management; GTB ...
Breaking Medicine News(10 mins):